GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sorrento Therapeutics Inc (LTS:0L85) » Definitions » Shares Buyback Ratio %

Sorrento Therapeutics (LTS:0L85) Shares Buyback Ratio % : -26.32 (As of May. 22, 2024)


View and export this data going back to 2018. Start your Free Trial

What is Sorrento Therapeutics Shares Buyback Ratio %?

Shares Outstanding (EOP) are shares that have been authorized, issued, and purchased by investors and are held by them.

GuruFocus calculates shares buyback ratio using previous shares outstanding minus the current shares outstanding, and then divides by previous shares outstanding. Sorrento Therapeutics's current shares buyback ratio was -26.32%.


Sorrento Therapeutics Shares Buyback Ratio % Historical Data

The historical data trend for Sorrento Therapeutics's Shares Buyback Ratio % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sorrento Therapeutics Shares Buyback Ratio % Chart

Sorrento Therapeutics Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Shares Buyback Ratio %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -47.50 -37.22 -64.06 -14.27 -63.79

Sorrento Therapeutics Quarterly Data
Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23
Shares Buyback Ratio % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -16.33 -7.30 -10.03 -6.99 -

Sorrento Therapeutics Shares Buyback Ratio % Calculation

Sorrento Therapeutics's Shares Buyback Ratio for the fiscal year that ended in Dec. 2022 is calculated as

Shares Buyback Ratio=(Shares Outstanding (EOP) (A: Dec. 2021 ) - Shares Outstanding (EOP) (A: Dec. 2022 )) / Shares Outstanding (EOP) (A: Dec. 2021 )
=(314.573 - 515.249) / 314.573
=-63.79%

Sorrento Therapeutics's Shares Buyback Ratio for the quarter that ended in Jun. 2023 is calculated as

Shares Buyback Ratio=(Shares Outstanding (EOP) (A: Mar. 2023 ) - Shares Outstanding (EOP) (A: Jun. 2023 )) / Shares Outstanding (EOP) (A: Mar. 2023 )
=(551.281 - 551.281) / 551.281
=0.00%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Sorrento Therapeutics Shares Buyback Ratio % Related Terms

Thank you for viewing the detailed overview of Sorrento Therapeutics's Shares Buyback Ratio % provided by GuruFocus.com. Please click on the following links to see related term pages.


Sorrento Therapeutics (LTS:0L85) Business Description

Traded in Other Exchanges
Address
4955 Directors Place, San Diego, CA, USA, 92121
Sorrento Therapeutics Inc is a clinical and commercial-stage biopharmaceutical company developing a portfolio of next-generation treatments for three major therapeutic areas: cancer, infectious disease, and pain. Its multimodal, multipronged approach to fighting cancer is made possible by its extensive immuno-oncology platforms, including key assets such as fully human antibodies (G-MAB library), immuno-cellular therapies (DAR-T), antibody-drug conjugates (ADCs), and oncolytic virus (Seprehvec). Sorrento is also developing potential antiviral therapies and vaccines against coronaviruses, including COVI-AMG, COVIDROPS, COVISHIELD, FUJOVEE (Abivertinib), and OQORY (Covi-MSC), and diagnostic test solutions, including COVITRACK and COVIMARK.

Sorrento Therapeutics (LTS:0L85) Headlines

No Headlines